STRS Ohio’s 4D Molecular Therapeutics FDMT Stock Holding History

STRS Ohio’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$66.5K	Sell	5,000 -20,100	-80%	-$196K	﹤0.01%	1970
2026 Q1	$234K	Hold	25,100	–	–	﹤0.01%	1427
2025 Q4	$188K	Hold	25,100	–	–	﹤0.01%	1550
2025 Q3	$218K	Buy	+25,100	New	+$150K	﹤0.01%	1490
2021 Q2	–	Sell	-1,900	Closed	-$82K	–	2289
2021 Q1	$82K	Buy	+1,900	New	+$84.1K	﹤0.01%	1976

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

STRS Ohio's FDMT Position: Q2 2026 in Review

STRS Ohio reduced its 4D Molecular Therapeutics (FDMT) stake by 80% in Q2 2026, selling an estimated $196K and leaving 5,000 shares worth $66.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1970.

STRS Ohio first reported a position in FDMT in Q1 2021 and has held it in 5 quarters since. The position peaked at $234K in Q1 2026. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

STRS Ohio held 5,000 shares of 4D Molecular Therapeutics worth $66.5K as of Q2 2026.
STRS Ohio sold 20,100 4D Molecular Therapeutics shares in Q2 2026, an estimated $196K.
4D Molecular Therapeutics made up ﹤0.01% of STRS Ohio's portfolio in Q2 2026, its #1970 holding.
STRS Ohio first reported a position in 4D Molecular Therapeutics in Q1 2021 and has held it in 5 quarters since.
STRS Ohio's 4D Molecular Therapeutics position peaked at $234K in Q1 2026.
158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.